GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2006

Avicena and NINDS Embark on Phase III Trial for Parkinson's Disease

  • Avicena will supply the National Institute of Neurological Disorders and Stroke (NINDS) with PD-02, the company's lead Parkinson's disease (PD) drug candidate, for a Phase III trial being planned by the Institute. The trial is designed to evaluate PD-02's potential to slow the progression of Parkinson's disease.

    PD-02 has demonstrated the potential to improve neurological function in patients with ALS, Huntington's disease, and Parkinson's disease. The company reports that in preclinical studies, PD-02 showed significant neuroprotective properties, including protection of the dopaminergic cells which are affected in Parkinson's disease.

    As part of its ongoing collaboration with NINDS, Avicena will provide PD- 02 and placebo for the trial and fund a related chronic toxicology study. In turn, Avicena has the right to utilize the study's findings for an NDA submission to the FDA.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?